We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
President Bush, who has long rejected the notion of allowing the importation of prescription drugs from abroad, appeared to do something of an about-face during a campaign stop in Wisconsin this week, saying drug importation is a good idea “if it’s safe.”
A senior scholar at the libertarian Cato Institute recommends that the U.S. repeal its ban on the importation of Rx drugs and allow pharmaceutical companies and foreign countries to work out on their own what the latter will pay for U.S. patented medicines.
The sponsor of the first Project BioShield law, which encourages private sector development of bioterrorism antidotes, said it will be followed by a second law that will provide more incentives for the development of therapeutics and vaccines.
The new Project BioShield law that encourages private sector development of bioterrorism antidotes will be followed by a second law that will provide more incentives for the development of therapeutics and vaccines, according to the sponsor of the original bill.
Legislation that would require companies to expense the stock options of only the five highest-paid company executives was passed by the House last week — an action that delighted the biotechnology industry, which had opposed another government proposal requiring companies to expense all employee stock options.
The Senate has approved a U.S.-Australia free trade agreement (FTA) that includes a provision that grants the holders of pharmaceutical patents the right to block importation of a patented product into the U.S.
To compel greater compliance with posting requirements on clinical drug trial registries, two Democratic senators are giving consideration to authorizing the FDA to withhold approval of clinical trial protocols pending a sponsor's commitment to list on the registry.
A provision passed by the House barring the FDA from spending federal money to block the importation of Rx drugs potentially could pave the way for counterfeiters to flood the U.S. market with fake products, according to the agency’s director of pharmacy affairs.
To the surprise of many White House critics in Congress, a congressional study of the likely costs of the Medicare Rx benefit revealed that they are in line with estimates Congress had relied upon when considering the original bill.